Related Experiment Videos
Haemodynamic dose-response effects of UK-52,046 in ischaemic disease with or without impaired left ventricular
B Silke1, A V Zezulka, S P Verma
1University Department of Cardiovascular Studies, General Infirmary, Leeds.
Insights
The new alpha 1-adrenoceptor antagonist UK-52,046 effectively lowered blood pressure and improved cardiac function in patients with coronary disease. This drug shows promise for managing cardiovascular conditions.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Coronary artery disease (CAD) poses significant cardiovascular risks.
- Alpha-1 adrenoceptors play a role in vascular tone and cardiac function.
- Novel therapeutic agents are needed to manage hemodynamics in CAD patients.
Purpose of the Study:
- To evaluate the hemodynamic effects of a new cardioselective alpha 1-adrenoceptor antagonist, UK-52,046.
- To assess the drug's impact at rest and during exercise in patients with stable coronary disease.
Main Methods:
- Twenty-five patients with stable coronary disease were enrolled.
- Two dose-response regimens of UK-52,046 were administered at rest.
- Hemodynamic measurements, including blood pressure and cardiac index, were recorded.
- Exercise hemodynamics were assessed before and after drug administration.
Main Results:
- UK-52,046 significantly reduced mean arterial blood pressure at rest.
- The drug increased cardiac index and heart rate at higher doses.
- Pulmonary artery occluded pressure and vascular resistance index decreased with higher doses.
Conclusions:
- UK-52,046 demonstrates favorable hemodynamic effects in patients with coronary disease.
- The drug's cardioselective alpha 1-adrenoceptor antagonism may benefit cardiovascular management.
- Further research is warranted to explore its therapeutic potential.
Abstract:
1. The haemodynamic effects of a new cardioselective postsynaptic alpha 1-adrenoceptor antagonist UK-52,046, were evaluated in 25 patients with stable coronary disease, with or without impaired left ventricular function. At rest the haemodynamic effects to two dose-response regimens were determined. In an initial eight patients 0.125, 0.125 and 0.25 micrograms kg-1 were administered peripherally at 15 min intervals; the haemodynamic measurements were determined between 10 to 15 min after each dose. In a further 17 patients, the dose regimen was doubled yielding a cumulative dose-regimen of 0.25, 0.5 and 1.0 micrograms kg-1. The exercise effects were determined by comparison of measurements during 4 min of supine sub-maximal bicycle exercise at a fixed workload before and after drug treatment. 2. At rest, the lower dose regimen of UK-52,046 significantly reduced systemic mean arterial blood pressure (-5 mm Hg; P less than 0.05) and increased cardiac index (+0.2 l min-1 m-2, P less than 0.01). The higher dose regimen of UK-52,046 reduced systemic mean arterial blood pressure (-7 mm Hg; P less than 0.01), pulmonary artery occluded pressure (PAOP) (-2 mm Hg, P less than 0.01) and vascular resistance index (-314 dyn s cm-5 m2; P less than 0.05) with an increase in heart rate (+7%, P less than 0.05) and cardiac index (+0.2 l min-1 m-2, P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)